Optimization of treatment workflow for 0.35T MR-Linac system

被引:0
|
作者
Behzadipour, Mojtaba [1 ]
Palta, Jatinder [1 ]
Ma, Tianjun [1 ]
Yuan, Lulin [1 ]
Kim, Siyong [1 ]
Kirby, Suzanne [1 ]
Torkelson, Laurel [1 ]
Baker, James [1 ]
Koenig, Tammy [1 ]
Khalifa, Mateb Al [1 ]
Hawranko, Robert [1 ]
Richeson, Dylan [1 ]
Fields, Emma [1 ]
Weiss, Elisabeth [1 ]
Song, William Y. [1 ]
机构
[1] Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23219 USA
来源
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS | 2024年 / 25卷 / 08期
关键词
CTgRT; FMEA; MRgRT; MR-Linac; TDABC; RADIATION-THERAPY; CLINICAL INTRODUCTION; AUTO-SEGMENTATION; RISK; RADIOTHERAPY; CANCER; MANAGEMENT; COSTS;
D O I
10.1002/acm2.14393
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PurposeThis study presents a novel and comprehensive framework for evaluating magnetic resonance guided radiotherapy (MRgRT) workflow by integrating the Failure Modes and Effects Analysis (FMEA) approach with Time-Driven Activity-Based Costing (TDABC). We assess the workflow for safety, quality, and economic implications, providing a holistic understanding of the MRgRT implementation. The aim is to offer valuable insights to healthcare practitioners and administrators, facilitating informed decision-making regarding the 0.35T MRIdian MR-Linac system's clinical workflow.MethodsFor FMEA, a multidisciplinary team followed the TG-100 methodology to assess the MRgRT workflow's potential failure modes. Following the mitigation of primary failure modes and workflow optimization, a treatment process was established for TDABC analysis. The TDABC was applied to both MRgRT and computed tomography guided RT (CTgRT) for typical five-fraction stereotactic body RT (SBRT) treatments, assessing total workflow and costs associated between the two treatment workflows.ResultsA total of 279 failure modes were identified, with 31 categorized as high-risk, 55 as medium-risk, and the rest as low-risk. The top 20% risk priority numbers (RPN) were determined for each radiation oncology care team member. Total MRgRT and CTgRT costs were assessed. Implementing technological advancements, such as real-time multi leaf collimator (MLC) tracking with volumetric modulated arc therapy (VMAT), auto-segmentation, and increasing the Linac dose rate, led to significant cost savings for MRgRT.ConclusionIn this study, we integrated FMEA with TDABC to comprehensively evaluate the workflow and the associated costs of MRgRT compared to conventional CTgRT for five-fraction SBRT treatments. FMEA analysis identified critical failure modes, offering insights to enhance patient safety. TDABC analysis revealed that while MRgRT provides unique advantages, it may involve higher costs. Our findings underscore the importance of exploring cost-effective strategies and key technological advancements to ensure the widespread adoption and financial sustainability of MRgRT in clinical practice.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Apparent Diffusion Coefficient Calculation On a 0.35T MR-Linac System
    Lewis, B.
    Shin, J.
    Kim, J.
    Gach, H.
    Kim, T.
    MEDICAL PHYSICS, 2021, 48 (06)
  • [2] Rapid multicontrast brain imaging on a 0.35T MR-linac
    Nejad-Davarani, Siamak P.
    Zakariaei, Niloufar
    Chen, Yongsheng
    Haacke, E. Mark
    Hurst, Newton J., Jr.
    Salim Siddiqui, M.
    Schultz, Lonni R.
    Snyder, James M.
    Walbert, Tobias
    Glide-Hurst, Carri K.
    MEDICAL PHYSICS, 2020, 47 (09) : 4064 - 4076
  • [3] Feasibility study: Polymer Gel Dosimetry On 0.35T MR-Linac System
    Marage, L.
    Boudet, J.
    Aubignac, L.
    Bessieres, I.
    Petitfils, A.
    MEDICAL PHYSICS, 2022, 49 (06) : E769 - E769
  • [4] Phantom measurements of apparent diffusion coefficient on a 0.35T MR-Linac
    Wallimann, P.
    Pouymayou, B.
    Mayinger, M.
    Nowakowska, S.
    Boss, A.
    Guckenberger, M.
    Tanadini-Lang, S.
    Andratschke, N.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S560 - S562
  • [5] Automated daily dose accumulation workflow for treatment quality assurance during online adaptive radiotherapy with a 0.35T MR-linac
    Behzadipour, Mojtaba
    Ma, Tianjun
    Datsang, Rabten K.
    Lee, Brandon
    Pittock, Dane
    Weiss, Elisabeth
    Song, William Y.
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2025, 26 (03):
  • [6] Absolute dosimetry at a 0.35T MR-Linac with a combined polymer gel (PG)-TLD system
    Schwahofer, A.
    Mann, P.
    Spindeldreier, K.
    Karger, C.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S704 - S705
  • [7] Implementing Absolute Dose Measurements On SunNuclear ArcCHECK-MR in a 0.35T MR-Linac
    Price, A.
    Heermann, A.
    Maraghechi, B.
    Curcuru, A.
    Rodriguez, V.
    Mutic, S.
    Green, O.
    MEDICAL PHYSICS, 2019, 46 (06) : E267 - E267
  • [8] A 3.5 Year Clinical Experience of a 0.35T MR-Linac System: A "Game Changer" for Radiation Oncology?
    Chuong, Michael
    Herrera, Roberto
    Kotecha, Rupesh
    Mittauer, Kathryn
    Hall, Matthew
    McCulloch, James
    Contreras, Jessika
    Alvarez, Diane
    Kaiser, Adeel
    Kalman, Noah
    Tom, Martin
    Romaguera, Tino
    Byrapaneni, Sid
    Panoff, Joseph
    Rodrigues, Maria-Amelia
    Fagundes, Marcio
    Mehta, Minesh
    Gutierrez, Alonso
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (09): : S45 - S45
  • [9] Small Field Output Factor (FOF) Measurements During Commissioning of a 0.35T MR-Linac System
    Alghamwa, M.
    Sohn, J.
    Hawranko, R.
    Kim, S.
    Yadav, P.
    Das, I.
    Song, W.
    MEDICAL PHYSICS, 2022, 49 (06) : E228 - E228
  • [10] Clinical Implementation of a 0.35T MR-Linac in Spain: Initial Experience and Toxicity Assessment
    Gonsalves, Daniela
    Rincon, Diego
    Ocanto, Abrahams
    Torres, Lisselott
    Montijano, Miguel
    Fernandez, Castalia
    Sevilla, Beatriz
    Amorin, Marina
    Guijarro, Marcos
    Gonzales, Jose A.
    Begara, Jose
    Meilan, Eduardo
    Gomez, Alberto
    Esteban, David
    Romero, Sigfredo
    Dominguez, Jesus
    Sanz, David
    Rodriguez, Julia
    Sanchez, Alicia
    Gongora, Francisco
    Lopez, Escarlata
    Counago, Felipe
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1967 - S1969